Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 17/20 | 0.51 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | ROS1 | P08922 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10098791 | 0.84 | TNK2 (0.56) | TNK2LRRK2 | |
| SCHEMBL19457452 | 0.81 | PIK3CD (0.56) | NUAK1PIK3CDAURKAPIK3C2GPIK3CG | |
| SCHEMBL30131807 | 0.81 | PIK3CD (0.56) | NUAK1PIK3CDAURKAPIK3C2GPIK3CG | |
| SCHEMBL29517238 | 0.69 | PTK2 (0.44) | TNK2 | |
| SCHEMBL22663660 | 0.68 | PIK3CD (0.58) | NUAK1PIK3CDAURKAPIK3C2GPIK3CG | |
| SCHEMBL22658895 | 0.68 | PTK2 (0.43) | TNK2 | |
| SCHEMBL29517494 | 0.68 | PTK2 (0.43) | TNK2 | |
| SCHEMBL21938544 | 0.67 | TNK2 (0.33) | TNK2 | |
| SCHEMBL10098691 | 0.66 | MAPK7 (0.56) | TNK2NUAK1PIK3CDAURKAPIK3C2G | |
| SCHEMBL20875242 | 0.66 | PIK3CD (0.59) | NUAK1PIK3CDAURKAPIK3C2GPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3440084-B1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING PI3K-MEDIATED DISORDERS | DANA FARBER CANCER INST INC (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3440084-B1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING PI3K-MEDIATED DISORDERS | DANA FARBER CANCER INST INC (US) | 2022-12-21 | — | — | EP | disclosed |
| US-11155556-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-11155556-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-10975092-B2 | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof | ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2021-04-13 | — | — | US | disclosed |
| US-20200115386-A1 | PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | Anhui New Star Pharmaceutical Development Co., Ltd . (CN) | 2020-04-16 | — | — | US | disclosed |
| US-20190106424-A1 | PYRIMIDO-DIAZEPINON KINASE SCAFFOLD COMPOUNDS AND METHODS FOR TREATING P13K-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-11 | — | — | US | disclosed |
| US-20190106424-A1 | PYRIMIDO-DIAZEPINON KINASE SCAFFOLD COMPOUNDS AND METHODS FOR TREATING P13K-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-11 | — | — | US | disclosed |
| EP-3440084-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING PI3K-MEDIATED DISORDERS | Dana-Farber Cancer Institute, Inc. (US) | 2019-02-13 | — | — | EP | disclosed |
| WO-2017177092-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING PI3K-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017177092-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING PI3K-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975092-B2 | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof | MST1, STK11, MSTN | TNK2 125/4885NUAK1 1455/4885PIK3CD 309/4885 |
| US-11155556-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders | PI4KA, PIK3CA, PI4KB | TNK2 180/4885NUAK1 394/4885PIK3CD 5/4885 |
| US-20200115386-A1 | PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | MST1, STK11, MSTN | TNK2 125/4885NUAK1 1455/4885PIK3CD 309/4885 |
| US-20190106424-A1 | PYRIMIDO-DIAZEPINON KINASE SCAFFOLD COMPOUNDS AND METHODS FOR TREATING P13K-MEDIATED DISORDERS | PI4KA, PI4KB, PIK3CA | TNK2 125/4885NUAK1 253/4885PIK3CD 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.